Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results f...
Guardado en:
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a44 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:6f3a6371d2554c1597cec7f371a14a44 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:6f3a6371d2554c1597cec7f371a14a442021-12-02T13:56:56ZAntibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants10.1038/s41598-021-80982-62045-2322https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a442021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-80982-6https://doaj.org/toc/2045-2322Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results from the routine early antibiotic use in symptomatic preterm Neonates (REASON) study are presented. The REASON study is the first trial to randomize symptomatic preterm neonates to receive or not receive antibiotics in the first 48 h after birth. Using 16S rRNA sequencing of stool samples collected longitudinally for 91 neonates, the effect of such antibiotic use on microbiome diversity is assessed. The results illustrate that type of nutrition shapes the early infant gut microbiome. By integrating data for the gut microbiome, stool metabolites, stool immune markers, and inferred metabolic pathways, an association was discovered between Veillonella and the neurotransmitter gamma-aminobutyric acid (GABA). These results suggest early antibiotic use may impact the gut-brain axis with the potential for consequences in early life development, a finding that needs to be validated in a larger cohort. Trial Registration This project is registered at clinicaltrials.gov under the name “Antibiotic ‘Dysbiosis’ in Preterm Infants” with trial number NCT02784821.Jordan T. RussellJ. Lauren RuossDiomel de la CruzNan LiCatalina BazacliuLaura PattonKelley Lobean McKinleyTimothy J. GarrettRichard A. PolinEric W. TriplettJosef NeuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Jordan T. Russell J. Lauren Ruoss Diomel de la Cruz Nan Li Catalina Bazacliu Laura Patton Kelley Lobean McKinley Timothy J. Garrett Richard A. Polin Eric W. Triplett Josef Neu Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants |
description |
Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results from the routine early antibiotic use in symptomatic preterm Neonates (REASON) study are presented. The REASON study is the first trial to randomize symptomatic preterm neonates to receive or not receive antibiotics in the first 48 h after birth. Using 16S rRNA sequencing of stool samples collected longitudinally for 91 neonates, the effect of such antibiotic use on microbiome diversity is assessed. The results illustrate that type of nutrition shapes the early infant gut microbiome. By integrating data for the gut microbiome, stool metabolites, stool immune markers, and inferred metabolic pathways, an association was discovered between Veillonella and the neurotransmitter gamma-aminobutyric acid (GABA). These results suggest early antibiotic use may impact the gut-brain axis with the potential for consequences in early life development, a finding that needs to be validated in a larger cohort. Trial Registration This project is registered at clinicaltrials.gov under the name “Antibiotic ‘Dysbiosis’ in Preterm Infants” with trial number NCT02784821. |
format |
article |
author |
Jordan T. Russell J. Lauren Ruoss Diomel de la Cruz Nan Li Catalina Bazacliu Laura Patton Kelley Lobean McKinley Timothy J. Garrett Richard A. Polin Eric W. Triplett Josef Neu |
author_facet |
Jordan T. Russell J. Lauren Ruoss Diomel de la Cruz Nan Li Catalina Bazacliu Laura Patton Kelley Lobean McKinley Timothy J. Garrett Richard A. Polin Eric W. Triplett Josef Neu |
author_sort |
Jordan T. Russell |
title |
Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants |
title_short |
Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants |
title_full |
Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants |
title_fullStr |
Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants |
title_full_unstemmed |
Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants |
title_sort |
antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a44 |
work_keys_str_mv |
AT jordantrussell antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT jlaurenruoss antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT diomeldelacruz antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT nanli antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT catalinabazacliu antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT laurapatton antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT kelleylobeanmckinley antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT timothyjgarrett antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT richardapolin antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT ericwtriplett antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT josefneu antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants |
_version_ |
1718392329027452928 |